Journal: Stem Cell Reviews

Article Title: Endothelial Progenitor Cells Modulate Inflammation-Associated Stroke Vasculome

doi: 10.1007/s12015-019-9873-x

Figure Lengend Snippet: EPC treatment downregulates the OGD-induced upregulation of inflammation-associated stroke vasculome in vitro in HEN6 cells and increases cell viability. a Representative photomicrographs of human bone marrow mesenchymal stem cells (BM-MSCs) seeded with EGM-2MV medium supplemented with growth factors on collagen-I coated 48 well plates and incubated for 7 days. After 7 days, immunocytochemistry analysis revealed specific expression of EPC markers including vWF, CD133 and VEGFR-2. Next, human endothelial brain cells (HEN6) were subjected to oxygen and glucose degradation (OGD) and co-cultured with EPCs and levels of RNA vasculome were analyzed with qRT-PCR. b Quantitative analyses of total fold change of RNA vasculome revealed that BRM, IκB, Foxf1, and ITIH-5 levels increased after OGD up to 10 folds relative to ambient conditions (Two way ANOVA, F 3,21 = 19.86, p < 0.001, Bonferonni’s test, p < 0.05). After EPC treatment, there was a significant 4, 6, and 2 fold decrease expression of BRM, IkB, and Foxf1 respectively in OGD-EPC treated HEN6 cells relative to OGD-vehicle treated HEN6 cells (p’s < 0.05), except ITI-H5 ( p > 0.05). c Cell viability analysis showed there was a significant increase of HEN6 cell survival in OGD-EPC and OGD-EPC scramble treatment compared to OGD alone or OGD-EPC IkB knockdown (One way ANOVA, F 1,22 = 44.58, p < 0.001, Bonferonni’s test, p < 0.05)

Article Snippet: Three different endothelial progenitor cell markers were used including CD133 (1:100, Catalog# NBP2–37741, Novus Biologicals), anti-VEGF (1:100, Catalog# ab2349, Abcam) and anti-von Willebrand factor antibody (1:100, Catalog# MAB3442, Merck Millipore).

Techniques: In Vitro, Incubation, Immunocytochemistry, Expressing, Cell Culture, Quantitative RT-PCR, Knockdown

Journal: Cell death & disease

Article Title: Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity.

doi: 10.1038/cddis.2016.409

Figure Lengend Snippet: Figure 2 The effects of cisplatin pretreatment on CSCs markers and multi-resistance in NSCLC. (a) ALDH activity was detected by flow cytometry in CDDP-pretreated and DMSO-pretreated NCI-H460, A549 and NCI-H1299 cells. DEAB was used as ALDH inhibitor. (b) The ALDH subtypes, including ALDH1A1, ADLH1A3, ALDH2, ALDH3A1, ALDH5A1 and ALDH7A1 were measured in CDDP-pretreated and control NCI-H460 cells. β-actin expression was used as a loading control. (c) The CD133 expression was detected by flow cytometry in CDDP-pretreated and control NCI-H460 and A549 cells. (d) The cell viability of CDDP-pretreated or control NCI-H460 and A549 cells after treated with different concentrations of CDDP and NVB for 48 h

Article Snippet: Antibodies to ALDH1A1, ALDH1A3, ALDH2, ALDH3A1, ALDH5A1 and ALDH7A1 were obtained from Novus Biologicals (Littleton, CO, USA).

Techniques: Activity Assay, Flow Cytometry, Control, Expressing